Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension

Clinical and Experimental Hypertension

Volumn 34, Issue 2, 2012, Pages 86-91

  Hasegawa, Hiroshi ^a   Takano, Hiroyuki ^a   Kameda, Yoshihito ^a   Kubota, Akihiko ^a   Kobayashi, Yoshio ^a   Komuro, Issei ^b  

^a CHIBA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiotensin II receptor blocker; Candesartan; Clinical trial; Hypertension

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; DIURETIC AGENT; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFECT; DRUG SUBSTITUTION; DYSLIPIDEMIA; FEMALE; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE MONITORING, AMBULATORY; CIRCADIAN RHYTHM; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; JAPAN; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TETRAZOLES; VALINE;

EID: 84859611533     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2011.628729     Document Type: Article

References (38)

1. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989; 79:733-743. (Pubitemid 19100532)
2. Pickering TG, Shimbo D, Haas D. Ambulatory blood-pressure monitoring. N Engl J Med 2006; 354:2368-2374.
3. Metoki H, Ohkubo T, Kikuya M et al. Prognostic significance for stroke of a morning pressor surge and a nocturnal blood pressure decline: The Ohasama study. Hypertension 2006; 47:149-154. (Pubitemid 43189756)
4. Li Y, Hansen TW, Staessen JA. More information on the reproducibility of the ambulatory arterial stiffness index. Am J Hypertens 2010; 23:113-114.
5. Abassi Z, Winaver J, Feuerstein GZ. The biochemical pharmacology of renin inhibitors: Implications for translational medicine in hypertension, diabetic nephropathy and heart failure: Expectations and reality. Biochem Pharmacol 2009; 78:933-940.
6. Cohn JN, Tognoni G. A randomized trial of the angiotensinreceptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675. (Pubitemid 33126822)
7. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359:1004-1010. (Pubitemid 34286537)
8. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362:759-766. (Pubitemid 37093915)
9. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-convertingenzyme inhibitors: The CHARM-Added trial. Lancet 2003; 362:767-771. (Pubitemid 37093916)
10. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensinconverting- enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003; 362:772-776. (Pubitemid 37093917)
11. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003; 362:777-781. (Pubitemid 37093918)
12. Zheng Z, Shi H, Jia J, Li D, Lin S. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst 2011; 12:365-374.
13. Fierens F, Vanderheyden PM, De Backer JP, Vauquelin G. Binding of the antagonist [3H]candesartan to angiotensin II AT1 receptor-transfected [correction of tranfected] Chinese hamster ovary cells. Eur J Pharmacol 1999; 367:413-422. (Pubitemid 29106396)
14. Inada Y, Ojima M, Kanagawa R et al. Pharmacologic properties of candesartan cilexetil-possible mechanisms of long-acting antihypertensive action. J Hum Hypertens 1999; 13(Suppl. 1):S75-S80. (Pubitemid 29057662)
15. Vauquelin G, Fierens F, Van Liefde I. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: Comparison with other biphenyl-tetrazole sartans. J Hypertens Suppl 2006; 24:S23-S30.
16. Ojima M, Inada Y, Shibouta Y et al. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor. Eur J Pharmacol 1997; 319:137-146. (Pubitemid 27051327)
17. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Reninangiotensin system and cardiovascular risk. Lancet 2007; 369:1208-1219.
18. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334:1649-1654. (Pubitemid 126613653)
19. Nishikawa K, Naka T, Chatani F, Yoshimura Y. Candesartan cilexetil: A review of its preclinical pharmacology. J Hum Hypertens 1997; 11(Suppl. 2):S9-S17. (Pubitemid 27464500)
20. Bhuiyan MA, Ishiguro M, Hossain M et al. Binding sites of valsartan, candesartan and losartan with angiotensin II receptor 1 subtype by molecular modeling. Life Sci 2009; 85: 136-140.
21. Vanderheyden PM, Fierens FL, De Backer J, Vauquelin G. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors. Biochem Pharmacol 2000; 59:927-935. (Pubitemid 30110808)
22. Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1997; 11(Suppl. 2):S49-S53. (Pubitemid 27464508)
23. Zou Y, Akazawa H, Qin Y et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II. Nat Cell Biol 2004; 6:499-506. (Pubitemid 38786592)
24. Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol 2009; 302:237-243.
25. Le MT, Pugsley MK, Vauquelin G, Van Liefde I. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol 2007; 151:952-962. (Pubitemid 47195538)
26. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension 2008; 51: 393-398. (Pubitemid 351159955)
27. Ogihara T, Saruta T, Rakugi H et al. Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: A sub-analysis of the CASE-J trial. Hypertens Res 2009; 32: 248-254.
28. Demers C, McMurray JJ, Swedberg K et al. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. JAMA 2005; 294: 1794-1798. (Pubitemid 41435112)
29. Eklind-Cervenka M, Benson L, Dahlstrom U et al. Association of candesartan vs losartan with all-cause mortality in patients with heart failure. JAMA 2011; 305:175-182.
30. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001; 6:63-72. (Pubitemid 32587662)
31. Muller JE, Ludmer PL, Willich SN et al. Circadian variation in the frequency of sudden cardiac death. Circulation 1987; 75:131-138. (Pubitemid 17234550)
32. Kario K, Pickering TG, Umeda Y et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: A prospective study. Circulation 2003; 107:1401-1406. (Pubitemid 36350739)
33. Marfella R, Siniscalchi M, Nappo F et al. Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients. Am J Hypertens 2005; 18:308-318. (Pubitemid 40409909)
34. Gosse P, Ansoborlo P, Lemetayer P, Clementy J. Left ventricular mass is better correlated with arising blood pressure than with office or occasional blood pressure. Am J Hypertens 1997; 10:505-510. (Pubitemid 27239849)
35. Li Y, Thijs L, Hansen TW et al. Prognostic value of the morning blood pressure surge in 5645 subjects from 8 populations. Hypertension 2010; 55:1040-1048.
36. White WB, Weber MA, Davidai G et al. Ambulatory blood pressure monitoring in the primary care setting: Assessment of therapy on the circadian variation of blood pressure from the MICCAT-2 trial. Blood Press Monit 2005; 10: 157-163. (Pubitemid 40863089)
37. Kario K, Shimada K, Pickering TG. Clinical implication of morning blood pressure surge in hypertension. J Cardiovasc Pharmacol 2003; 42(Suppl. 1):S87-S91. (Pubitemid 37467083)
38. Kumagai Y. Strategies against high blood pressure in the early morning. Clin Exp Hypertens 2004; 26:107-118. (Pubitemid 38298884)